Global Haemophilia Therapeutics Market
Global Haemophilia Therapeutics Market
Increased use of recombinant and prophylaxis therapies drives growth
09-Apr-2015
South Asia, Middle East & North Africa
$3,950.00
Special Price $2,962.50 save 25 %
Description
This research service focuses on the global haemophilia therapeutics market, with a particular focus on recently FDA-approved drugs and late-stage compounds for the treatment of haemophilia A, haemophilia B, inhibitors, and von Willebrand Disease. Pipeline analysis outlines the major FDA-approved haemophilia products, which include those submitted for regulatory review and those in Phase I, II, and III of clinical development. The study also provides an overview of the major clinical trials of recently approved or late-stage pipeline candidates. Novel technologies to extend product half-life and potential future therapies for haemophilia patients have also been discussed.
Table of Contents
Executive Summary—Key Findings
Executive Summary—Key Findings (continued)
Haemophilia Drugs Market—Game-changing Strategies
Key Merger, Acquisition, and Partnership Assessment
Key Merger, Acquisition, and Partnership Assessment (continued)
Methodology and Scope
Introduction
Introduction (continued)
Classification of Haemophilia
Treatment Guidelines for Haemophilia Therapy—Prophylactic or On-demand
Market Overview—Segmentation
Market Overview—Segmentation (continued)
Haemophilia—Prevalence and Incidence
Haemophilia—Global Prevalence and Treatment Rates
Forecast Assumptions and Definitions
Haemophilia Therapeutics Market—Revenue Forecast
Revenue Forecast Discussion
Revenue Forecast Discussion (continued)
Increasing Use of Recombinant and Prophylactic Treatment
Variation in Adoption of Prophylactic Therapy by Region
Annual Switching Rates in Haemophilia
Global Haemophilia A and vWD Therapeutics Market Revenue Forecast
Revenue Forecast Discussion
Revenue Forecast Discussion (continued)
Haemophilia B Therapeutics Market—Revenue Forecast
Revenue Forecast Discussion
Revenue Forecast Discussion (continued)
Inhibitors (Bypassing Agents) Market—Revenue Forecast
Revenue Forecast Discussion
Revenue Forecast Discussion (continued)
Product Analysis—F VIII (Haemophilia A) and FVIII/vWF (vWD)
Product Analysis—F VIII (Haemophilia A) and FVIII/vWF (vWD) (continued)
Product Analysis—F VIII (Haemophilia A) and FVIII/vWF (vWD) (continued)
Product Analysis—F VIII (Haemophilia A) and FVIII/vWF (vWD) (continued)
Product Analysis—Factor IX (Haemophilia B)
Product Analysis—Factor IX (Haemophilia B) (continued)
Product Analysis—Factor VIIa (Inhibitors)
Haemophilia Drugs—Competitive Landscape of Products in Development
Haematological Drugs—Pipeline Analysis
Pipeline Analysis—F VIII (Haemophilia A) and FVIII/VWF (VWD)
Pipeline Analysis—F IX (Haemophilia B)
Pipeline Analysis—F VIIa (Inhibitors)
Haemophilia Therapeutics Market—Major Ongoing/Recently Completed Clinical Trials
Haemophilia Therapeutics Market—Major Ongoing/Recently Completed Clinical Trials (continued)
Haemophilia Therapeutics Market—Major Ongoing/Recently Completed Clinical Trials (continued)
Eloctate—Biogen Idec/SOBI
NovoEight (Turoctocog alfa)—Novo Nordisk
BAX 111—Baxter
BAX 855—Baxter
BAY81-8973—Bayer
Nuwiq/Human-cl rhFVIII (simotocog alfa)—Octapharma
BAY94-9027—Bayer
N8-GP (turoctocog alfa pegol)—Novo Nordisk
rVIII-Single Chain—CSL Behring
Alprolix—Biogen Idec/SOBI
Rixubis—Baxter
rIX-FP—CSL Behring
IB1001—Cangene (Emergent Biosolutions)
N9-GP (nonacog beta pegol)—Novo Nordisk
Obizur—Baxter
BAX 817—Baxter
LR769—rEVO Biologics/LFB
Novel Technologies that Extend Half-life of Factor Concentrates
Novel Technologies that Extend Half-life of Factor Concentrates (continued)
Novel Technologies that Extend Half-life of Factor Concentrates (continued)
Novel Technologies that Extend Half-life of Factor Concentrates (continued)
Novel Pipeline Therapies—Gene Therapy
Novel Pipeline Therapies—RNA Interference
Novel Pipeline Therapies—Tissue Factor Pathway Inhibitor
Haemophilia A Therapeutics (FVIII) Market—Timeline of Key Events
Haemophilia B Therapeutics (FIX) Market—Timeline of Key Events
Inhibitors (Bypassing Agents) (FVIIa) Market—Timeline of Key Events
Leading Big Pharma Companies—SWOT Analysis Bayer
Leading Big Pharma Companies—SWOT Analysis Baxter
Leading Big Pharma Companies—SWOT Analysis Novo Nordisk
Leading Big Pharma Companies—SWOT Analysis Pfizer
Key Companies to Watch—SWOT Analysis Biogen Idec
Key Companies to Watch—SWOT Analysis CSL Behring
Comparative Product Analysis of Key Market Participants
Conclusions and Recommendations
Legal Disclaimer
List of Abbreviations
The Frost & Sullivan Story
Value Proposition
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Popular Topics
No Index | No |
---|---|
Podcast | No |
Author | Aiswariya Chidambaram |
WIP Number | MAD9-01-00-00-00 |
Keyword 1 | Haemophilia Therapeutics |
Keyword 2 | Prophylaxis therapies |
Keyword 3 | Recombinant therapies |
Is Prebook | No |